Literature DB >> 28419443

Loss of natural killer T cells promotes pancreatic cancer in LSL-KrasG12D/+ mice.

Naveena B Janakiram1, Altaf Mohammed1, Taylor Bryant1, Rebekah Ritchie1, Nicole Stratton1, Lydgia Jackson2, Stan Lightfoot1, Doris M Benbrook3, Adam S Asch1, Mark L Lang2, Chinthalapally V Rao1.   

Abstract

The role of the unique T-cell population, natural killer T (NKT) cells, which have similar functions to NK cells in pancreatic cancer (PC), is not yet evaluated. To address the regulatory roles of NKT cells on tumour progression through tumour-associated macrophages (TAM) and their production of microsomal prostaglandin E synthase-1 (mPGES-1) and 5-lipoxygenase (5-LOX) in (Kras)-driven pancreatic tumour (KPT) progression, we crossed CD1d-/- mice deficient in both invariant and variant NKT cells with the KrasG12D mice. Loss of NKT cells significantly increased pancreatic intraepithelial neoplasia (PanIN) lesions and also increased 5-LOX and mPGES-1 expression in M2-type macrophages and cancer stem-like cells in pancreatic tumours. Pharmacological inhibition of mPGES-1 and 5-LOX in M2 macrophages with specific inhibitor YS-121 in KPT-CD1d-/- mice decreased PanIN lesions and suppressed tumour growth in association with elevated levels of active CD8a cells. Hence, NKT cells regulate PC by modulating TAMs (M2) through mPGES-1 and 5-LOX; and the absence of NKT cells leads to aggressive development of PC.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  microsomal prostaglandin E synthase-1; natural killer T cells; pancreatic cancer; prevention; treatment

Mesh:

Substances:

Year:  2017        PMID: 28419443      PMCID: PMC5543460          DOI: 10.1111/imm.12746

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

2.  Reduction of CD1d expression in vivo minimally affects NKT-enhanced antibody production but boosts B-cell memory.

Authors:  Gillian A Lang; Amy M Johnson; T Scott Devera; Sunil K Joshi; Mark L Lang
Journal:  Int Immunol       Date:  2011-03-12       Impact factor: 4.823

3.  Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis.

Authors:  Y Sasaki; D Kamei; Y Ishikawa; T Ishii; S Uematsu; S Akira; M Murakami; S Hara
Journal:  Oncogene       Date:  2011-10-10       Impact factor: 9.867

4.  Selective PGE(2) suppression inhibits colon carcinogenesis and modifies local mucosal immunity.

Authors:  Masako Nakanishi; Antoine Menoret; Takuji Tanaka; Shingo Miyamoto; David C Montrose; Anthony T Vella; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-16

5.  Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells.

Authors:  T Kawano; J Cui; Y Koezuka; I Toura; Y Kaneko; H Sato; E Kondo; M Harada; H Koseki; T Nakayama; Y Tanaka; M Taniguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

6.  Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.

Authors:  Emilie Mamessier; Aude Sylvain; Marie-Laure Thibult; Gilles Houvenaeghel; Jocelyne Jacquemier; Rémy Castellano; Anthony Gonçalves; Pascale André; François Romagné; Gilles Thibault; Patrice Viens; Daniel Birnbaum; François Bertucci; Alessandro Moretta; Daniel Olive
Journal:  J Clin Invest       Date:  2011-08-15       Impact factor: 14.808

Review 7.  mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators".

Authors:  Masako Nakanishi; Vijay Gokhale; Emmanuelle J Meuillet; Daniel W Rosenberg
Journal:  Biochimie       Date:  2010-02-13       Impact factor: 4.079

8.  Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas.

Authors:  D J Brat; K D Lillemoe; C J Yeo; P B Warfield; R H Hruban
Journal:  Am J Surg Pathol       Date:  1998-02       Impact factor: 6.394

9.  Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.

Authors:  Antonina V Kurtova; Jing Xiao; Qianxing Mo; Senthil Pazhanisamy; Ross Krasnow; Seth P Lerner; Fengju Chen; Terrence T Roh; Erica Lay; Philip Levy Ho; Keith Syson Chan
Journal:  Nature       Date:  2014-12-03       Impact factor: 49.962

10.  Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer.

Authors:  Yun-Peng Peng; Yi Zhu; Jing-Jing Zhang; Ze-Kuan Xu; Zhu-Yin Qian; Cun-Cai Dai; Kui-Rong Jiang; Jun-Li Wu; Wen-Tao Gao; Qiang Li; Qing Du; Yi Miao
Journal:  J Transl Med       Date:  2013-10-20       Impact factor: 5.531

View more
  22 in total

Review 1.  Chronic Pancreatitis and the Development of Pancreatic Cancer.

Authors:  Hemanth K Kandikattu; Sathisha U Venkateshaiah; Anil Mishra
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2020       Impact factor: 2.895

2.  Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.

Authors:  Mautin Hundeyin; Emma Kurz; Ankita Mishra; Juan Andres Kochen Rossi; Shannon M Liudahl; Kenna R Leis; Harshita Mehrotra; Mirhee Kim; Luisana E Torres; Adesola Ogunsakin; Jason Link; Rosalie C Sears; Shamilene Sivagnanam; Jeremy Goecks; K M Sadeq Islam; Igor Dolgalev; Shivraj Savadkar; Wei Wang; Berk Aykut; Joshua Leinwand; Brian Diskin; Salma Adam; Muhammad Israr; Maeliss Gelas; Justin Lish; Kathryn Chin; Mohammad Saad Farooq; Benjamin Wadowski; Jingjing Wu; Suhagi Shah; Dennis O Adeegbe; Smruti Pushalkar; Varshini Vasudevaraja; Deepak Saxena; Kwok-Kin Wong; Lisa M Coussens; George Miller
Journal:  Cancer Discov       Date:  2019-07-02       Impact factor: 39.397

3.  IL-15 regulates fibrosis and inflammation in a mouse model of chronic pancreatitis.

Authors:  Murli Manohar; Hemanth Kumar Kandikattu; Alok Kumar Verma; Anil Mishra
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-09-13       Impact factor: 4.052

Review 4.  Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Authors:  Gloria Delfanti; Paolo Dellabona; Giulia Casorati; Maya Fedeli
Journal:  Front Med (Lausanne)       Date:  2022-05-09

5.  Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment.

Authors:  Nicholas Osborne; Rebecca Sundseth; Julian Burks; Hong Cao; Xunxian Liu; Alexander H Kroemer; Lynda Sutton; Allen Cato; Jill P Smith
Journal:  Cancer Immunol Immunother       Date:  2019-09-24       Impact factor: 6.968

6.  KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma.

Authors:  Yuexian Li; Zhou Su; Biwei Wei; Zhihai Liang
Journal:  Int J Gen Med       Date:  2021-06-21

Review 7.  NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies.

Authors:  Kanako Shimizu; Tomonori Iyoda; Satoru Yamasaki; Norimitsu Kadowaki; Arinobu Tojo; And Shin-Ichiro Fujii
Journal:  Cancers (Basel)       Date:  2020-03-28       Impact factor: 6.639

Review 8.  The Pathophysiological Relevance of the iNKT Cell/Mononuclear Phagocyte Crosstalk in Tissues.

Authors:  Filippo Cortesi; Gloria Delfanti; Giulia Casorati; Paolo Dellabona
Journal:  Front Immunol       Date:  2018-10-12       Impact factor: 7.561

9.  Tumor-promoting effects of pancreatic cancer cell exosomes on THP-1-derived macrophages.

Authors:  Samuel S Linton; Thomas Abraham; Jason Liao; Gary A Clawson; Peter J Butler; Todd Fox; Mark Kester; Gail L Matters
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

Review 10.  Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer.

Authors:  Bilikis Aderonke Abolarinwa; Ridwan Babatunde Ibrahim; Yen-Hua Huang
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.